With dust set­tled on ac­tivist at­tack, Lau­rence Coop­er leaves Zio­pharm to a new board

Lau­rence Coop­er has done his part.

In the five years since he left a tenured po­si­tion at Hous­ton’s MD An­der­son Can­cer Cen­ter to be­come CEO of Boston-based Zio­pharm, he’s steered the small-cap im­munother­a­py play­er through pa­tient deaths in tri­als, clin­i­cal holds, short at­tacks and, most re­cent­ly, an ac­tivist at­tack on the board.

So when the com­pa­ny has “fan­tas­tic news” like an IND clear­ance for a TCR T cell ther­a­py pro­gram, he’s ready to pass on the ba­ton.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.